Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2011

View Archived Issues

Sanofi profiles pipeline highlights of third quarter 2011

Almirall and BioFocus enter collaboration

Eisai develops novel lanosterol synthase inhibitor for HCV

Preclinical profile of Merck & Co.'s HCV NS5A inhibitor MK-4882 described

Achillion Pharmaceuticals describes second-generation NS5A inhibitors

Gilead and Tibotec finalize agreement on single-tablet HIV regimen

EB-1020 as a new approach to treat ADHD

Favorable preclinical profile of C-21191 supports development for pain, spasticity

AVI BioPharma enters collaborations for two new exon-skipping drugs

Midatech obtains Swiss approval to test insulin-coated gold nanoparticles

Patient recruitment commences in phase I study of MK-1439 for HIV-1 infection

Researchers in India disclose novel NO-releasing prodrugs

UCB offers review of third quarter 2011

Phase I LG-631 gene therapy trial initiated for brain cancer

PharmacoFore presents new enzyme-cleavable amphetamine prodrugs

Prosidion researchers prepare novel GPR119 receptor agonists/DPP IV inhibitors

Array BioPharma patents new tyrosine-protein kinase inhibitors

Genzyme and Cystic Fibrosis Foundation enter collaboration for new cystic fibrosis drugs

Novel tyrosine-protein kinase inhibitors synthesized by MethylGene

Phase I MTN-013/IPM 026 safety trial for HIV enters subject screening stage

Profectus BioSciences receives additional grant from PATH Malaria Vaccine Initiative

PharmaGap starts animal efficacy study of GAP-107B8

BioSante Pharmaceuticals reports results from LibiGel pharmacokinetic study

Athersys regains rights to MultiStem cardiovascular program

Bristol-Myers Squib seeks approval of new indication for Taxol in Japan

InSite Vision starts phase III study of AzaSite Plus and DexaSite for blepharitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...